Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceHKSE:03681 -3.57%29 EBIT per Share is HK$-0.15 as of Dec. 2025. GuruFocus rates HKSE:03681 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,172 Biotechnology companies, SinoMab BioScience ranks better than 65.1% on this metric.
SinoMab BioScience's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.15.
During the past 3 years, the average EBIT per Share Growth Rate was 27.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for SinoMab BioScience's EBIT per Share or its related term are showing as below:
HKSE:03681'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -82.4 Med: -0.7 Max: 27.5
Current: 27.5
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of SinoMab BioScience was 27.50% per year. The lowest was -82.40% per year. And the median was -0.70% per year.
HKSE:03681's 3-Year EBIT Growth Rate is ranked better than 65.1% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs HKSE:03681: 27.50
SinoMab BioScience (HKSE:03681) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
SinoMab BioScience EBIT per Share Related Terms
SinoMab BioScience EBIT per Share Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (HKSE:03681) has a EBIT per Share of HK$-0.15 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #409 out of 1172 companies in the Biotechnology industry, placing it in the top 34.9%.
Is SinoMab BioScience's EBIT per Share too high?
SinoMab BioScience's current EBIT per Share is HK$-0.15. Based on the distribution chart, SinoMab BioScience ranks #409 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #409 out of 1172 companies for EBIT per Share. This puts SinoMab BioScience in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SinoMab BioScience and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current EBIT per Share is HK$-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (HKSE:03681) has a current EBIT per Share of HK$-0.15. The current EBIT per Share is HK$-0.15. SinoMab BioScience's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For SinoMab BioScience (HKSE:03681), the current EBIT per Share is HK$-0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
29GF Score
Get the complete analysis for HKSE:03681
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03681 has been successfully added to your 
